Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

P. van Balen, MD, C.A.M. van Bergen, I. Jedema, PhD, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, PhD, W.A.F. Marijt, MD, PhD, C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2012) 120 (21): 4116.

https://doi.org/10.1182/blood.V120.21.4116.4116

Published: 2012

Journal Articles

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

C.J.M. Halkes, MD, PhD, I Jedema, PhD, H.M. van Egmond, L van der Fits, PhD, J.H.F. Falkenburg, MD, PhD, MH Vermeer, MD, PhD

Blood (2011) 118 (21): 2491.

https://doi.org/10.1182/blood.V118.21.2491.2491

Published: 2011

Journal Articles

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Pleun Hombrink, MSc, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, MD, PhD, Peter A. van Veelen, Mirjam H.M. Heemskerk, PhD

Blood (2011) 118 (21): 4038.

https://doi.org/10.1182/blood.V118.21.4038.4038

Published: 2011

Journal Articles

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD, H.M. van Egmond, J. Olde Wolbers, C.W.J. Starrenburg, P. van Balen, MD, M. van de Meent, P.A. von dem Borne, MD, PhD, W.A.F. Marijt, MD, PhD, J.H. Veelken, MD, PhD, I Jedema, PhD

Blood (2011) 118 (21): 1979.

https://doi.org/10.1182/blood.V118.21.1979.1979

Published: 2011

Journal Articles

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

M. Eefting, MD, C.J.M. Halkes, MD, PhD, S. Kersting, MD, PhD, W.A.F. Marijt, MD, PhD, P.A. von dem Borne, MD, PhD, J.H. Veelken, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2011) 118 (21): 3064.

https://doi.org/10.1182/blood.V118.21.3064.3064

Published: 2011

Journal Articles

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

P.A. Von Dem Borne, MD, PhD, C.J.M. Halkes, MD, PhD, C.W.J. Starrenburg, W.A.F. Marijt, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2010) 116 (21): 2328.

https://doi.org/10.1182/blood.V116.21.2328.2328

Published: 2010

Journal Articles

Genomics as a Tool for Antigen Discovery in Allogeneic Stem Cell Transplantation: Identification of the Minor Antigen T4A through Donor/Patient Polymorphism Disparities

Paul Armistead, Shoudan Liang, Sijie Lu, Cornelis A.M. van Bergen, J.H.F. Falkenburg, Jeffrey J. Molldrem

Blood (2008) 112 (11): 3907.

https://doi.org/10.1182/blood.V112.11.3907.3907

Published: 2008

Journal Articles

Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.

I. Jedema, E. Steeneveld, M. Hoogendoorn, R. Willemze, J.H.F. Falkenburg

Blood (2004) 104 (11): 297.

https://doi.org/10.1182/blood.V104.11.297.297

Published: 2004

Journal Articles

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

J.F. de Vries, MSc, P.A. von dem Borne, MD, PhD, M.H.M. Heemskerk, PhD, R. Willemze, MD, PhD, J.H.F. Falkenburg, MD, PhD, R.M.Y. Barge, MD, PhD

Blood (2004) 104 (11): 1267.

https://doi.org/10.1182/blood.V104.11.1267.1267

Published: 2004

Journal Articles

HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

E.F.M. Posthuma, J.H.F. Falkenburg, J.F. Apperley, A. Gratwohl, E. Roosnek, B. Hertenstein, R.F. Schipper, G.M.T. Schreuder, J. D’Amaro, M. Oudshoorn, J.H. v Biezen, J. Hermans, R. Willemze, D. Niederwieser

Blood (1999) 93 (11): 3863–3865.

https://doi.org/10.1182/blood.V93.11.3863

Published: 1999

Journal Articles

HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34 + Early Progenitor Cells

Tuna Mutis, Ellen Schrama, Simone A.P. van Luxemburg-Heijs, J.H.F Falkenburg, Cornelis J.M. Melief, Els Goulmy

Blood (1997) 90 (3): 1083–1090.

https://doi.org/10.1182/blood.V90.3.1083

Published: 1997

NARROW

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

Genomics as a Tool for Antigen Discovery in Allogeneic Stem Cell Transplantation: Identification of the Minor Antigen T4A through Donor/Patient Polymorphism Disparities

Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34 + Early Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only